Laboratory Side Effects of Daratumumab
Daratumumab causes false-positive indirect Coombs tests and can interfere with serum immunofixation results, requiring type and screen before treatment initiation. 1
Critical Laboratory Interferences
Blood Bank Testing Interference
- Daratumumab binds to CD38 on red blood cells, causing false-positive indirect antiglobulin tests (indirect Coombs test) 1
- Mandatory action: Perform complete type and screen before initiating daratumumab therapy 1
- This interference masks detection of minor antigen antibodies in patient serum and disrupts serologic testing 1
- Cross-matching workaround: Dithiothreitol (DTT) treatment of reagent erythrocytes reliably eliminates daratumumab interference, but removes Kell antigen—therefore patients must receive Kell-negative blood 2
Serum Protein Monitoring Interference
- IgG kappa myeloma patients face specific challenges: Daratumumab is an IgG1 kappa antibody that produces spurious positive immunofixation results 1
- The therapeutic monoclonal antibody band can be mistaken for the original M-protein, leading to misinterpretation of disease response 1
- Solution: Use special interference testing or mass spectrometry-based assessment to differentiate between daratumumab and the patient's M-protein 1, 2
Minimal Residual Disease Testing
- Daratumumab interferes with MRD monitoring by multicolor flow cytometry (due to CD38 targeting) 2
Hematologic Laboratory Abnormalities
Common Grade 3/4 Cytopenias
Based on integrated safety analysis of 1,798 daratumumab-treated patients 3:
- Neutropenia: 45.9% (vs 32.3% comparator) - most common severe cytopenia
- Lymphopenia: 13% (vs 7.5% comparator)
- Thrombocytopenia: Reported in 54% of patients in CASTOR trial 2; 64.7% in real-world data 4
- Anemia: 35.7% in real-world cohorts 4
Important caveat: When adjusted for exposure, these cytopenias occurred more frequently with daratumumab than comparators, though prevalence remained <7% except for neutropenia, lymphopenia, and pneumonia 3
Monitoring Requirements
- CBC with differential and metabolic panel appropriate for monitoring treatment toxicities 1
- Regular assessment needed given increased infection risk (pneumonia: 10.6% vs 7.2% grade 3/4) 3
Clinical Implications
Stem Cell Collection Considerations
- Harvest autologous peripheral blood stem cells within first 6 cycles before prolonged daratumumab exposure in transplant candidates 1
- Daratumumab can compromise stem cell reserve 1
Subcutaneous Formulation Note
- Patients with significant thrombocytopenia may not be appropriate for subcutaneous daratumumab administration 1
- Consider intravenous formulation in these cases
Infection Risk Laboratory Markers
- Hypogammaglobulinemia reported in severe cases 5
- Consider immunoglobulin replacement for IgG <400 mg/dL (accounting for clonal portion in IgG myeloma patients) 1
The laboratory side effects are manageable with proper pre-treatment screening and ongoing monitoring, but the blood bank interference requires proactive planning before first dose to avoid transfusion delays.